Diroximel fumarate
CAS: 1577222-14-0
Rif. 3D-CNC22214
| 1mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione | ||
| 100mg | Fuori produzione | ||
| 250mg | Fuori produzione |
Informazioni sul prodotto
Dioximel is a drug that has been approved for the treatment of psoriasis. It has a profile of symptoms that are similar to those of psoriasis, and it also inhibits the growth factor called TNF-α. Dioximin is currently being evaluated in a clinical study for its efficacy in treating psoriatic arthritis. Dioximel is being studied as an anti-inflammatory agent to treat rheumatoid arthritis, osteoarthritis, and other inflammatory diseases. The mechanism of action of dioximel may be due to the inhibition of TNF-α production or by triggering apoptosis in cells where TNF-α is present. This drug has been shown to have no significant adverse effects on body mass index or lipid levels. There are no known interactions with other drugs that inhibit tumor necrosis factor activity.
